Abstract
Introduction and objectivesBenralizumab is used in severe eosinophilic asthma (SEA), in addition to other optimised therapies, to improve disease control and reduce exacerbation frequency. It is unknown if SEA patients...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
